Given the persistent suppression of proliferating T cell populations, we anticipated that ATRi QDx9 would abolish CD8+ Tem and tumor antigen–specific CD8+ T cell expansions in the DLN at 1 week after RT. This evidence concerns the gene CD8A and neoplasm.